Protein expression and mutational analysis of epidermal growth factor receptor in renal angiomyolipomas

Renal angiomyolipoma (AML) is a benign but progressive tumor that occasionally requires non‐surgical therapy and there appears to be a possibility that epidermal growth factor (EGF) is associated with pathogenesis of renal AML. The response to gefitinib, anti‐epidermal growth factor receptor (EGFR)...

Full description

Saved in:
Bibliographic Details
Published in:Pathology international 2007-09, Vol.57 (9), p.584-588
Main Authors: Lim, So Dug, Kim, Wanseop, Ahn, Geunghwan, Kwon, Ghee Young
Format: Article
Language:English
Subjects:
Adult
Aged
angiomyolipoma
Angiomyolipoma - genetics
Angiomyolipoma - metabolism
Angiomyolipoma - pathology
DNA Mutational Analysis
DNA, Neoplasm - analysis
epidermal growth factor receptor
Female
Fluorescent Antibody Technique, Indirect
Humans
immunohistochemistry
kidney
Kidney Neoplasms - genetics
Kidney Neoplasms - metabolism
Kidney Neoplasms - pathology
Male
Middle Aged
Mutation
Polymerase Chain Reaction
pyrosequencing
Receptor, Epidermal Growth Factor - genetics
Receptor, Epidermal Growth Factor - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Renal angiomyolipoma (AML) is a benign but progressive tumor that occasionally requires non‐surgical therapy and there appears to be a possibility that epidermal growth factor (EGF) is associated with pathogenesis of renal AML. The response to gefitinib, anti‐epidermal growth factor receptor (EGFR) agent and a prime example of target therapy, reportedly has been correlated with the presence of mutations within the tyrosine kinase (TK) domain of EGFR or the expression of its truncated form, EGFR variant III. Therefore the purpose of the present paper was to investigate EGFR protein expression and gene mutations in exons 18, 19 and 21 in 40 renal AML. No EGFR gene mutations of TK domain were detected in any of the 40 cases studied and strong immunostaining was found in 5% of the renal AML cases. The present findings indicate that in renal AML, anti‐EGFR treatment may not be promising but that there is a possibility that EGFR is associated with renal AML pathogenesis.
ISSN:1320-5463
1440-1827
DOI:10.1111/j.1440-1827.2007.02142.x